LY03005 is the company s second drug in the central nervous system (CNS) therapeutic area currently in the U ...
Luye Pharma Group has announced that it has entered into an exclusive distribution and marketing service agree...
PharmaMar, one of Luye Pharma’s collaborative partners, has announced that the U S Food and Drug Admini...
December 1, 2019, Luye Pharma Group has announced the acquisition of Shandong Boan Biological Technology Co L...
As one of the nation’s largest private mental health providers, October 10 is a very important date for ...
The first FDA De Novo designated NGS assay for detecting HIV-1 drug resistance mutations (DRMs)
TOP